You are hereBiblio / Developing U.S. Oversight Strategies for Nanobiotechnology: Learning from Past Oversight Experiences

Developing U.S. Oversight Strategies for Nanobiotechnology: Learning from Past Oversight Experiences


By csep - Posted on 14 September 2010

TitleDeveloping U.S. Oversight Strategies for Nanobiotechnology: Learning from Past Oversight Experiences
Publication TypeJournal Article
Year of Publication2009
AuthorsParadise, Jordan, Wolf Susan M., Kuzma Jennifer, Kuzhabekova Aliya, Tisdale Alison W., Kokkoli Efrosini, and Ramachandran Gurumurthy
JournalThe Journal of Law, Medicine & Ethics
Volume37
Issue4
Pagination688 - 705
Date Published12/2009
Publication Languageeng
ISSN Number1748720X
Abstract

This article discusses the oversight issues raised for the United States by the emergence of nanobiotechnology, and what regulatory agencies can learn from looking at five oversight case studies in how to handle these challenges. The cases reviewed include the oversight of genetically modified organisms in the food supply, pharmaceuticals, medical devices, chemicals in the workplace, and gene therapy.

DOI10.1111/j.1748-720X.2009.00441.x